Key result
Elevated H-FABP was an independent predictor of future cerebro-cardiovascular disease in patients with essential hypertension.
Why the study?
Does elevated serum H-FABP predict future cerebro-cardiovascular disease in patients with essential hypertension?
Cohort (n=192)
Does elevated serum H-FABP predict future cerebro-cardiovascular disease in patients with essential hypertension?
Answers are grounded in this paper and cite their sources.
Elevated serum H-FABP is an independent predictor of future cerebro-cardiovascular events in patients with essential hypertension, offering prognostic value beyond conventional risk factors.
Purpose: Heart-type fatty acid-binding protein (H-FABP), a sensitive marker of myocardial damage, is a useful diagnostic and prognositic marker in patients with cardiovascular disease, not only acute coronary syndrome but also chronic heart failure. We investigated whether H-FABP is a useful prognostic marker in patients with hypertension (HT), a major risk factor of acute coronary syndrome and heart failure. Methods: We measured serum levels of H-FABP in 192 patients with essential HT without prior cerebro-cardiovascular disease (CCVD) and renal failure (estimated glomerular filtration rate [eGFR] < 30ml/min/1.73m2), and compared the prognostic value of H-FABP with clinical parameters including coronary risk factors, neurohumoral factors (plasma renin activity, plasma aldosterone, norepinephrine and B-type natriuretic peptide [BNP] concentrations) and echocardiographic findings. Results: Over a mean follow-up period of 55 months, 37 patients developed CCVD (15 heart failure, 3 acute coronary syndrome, 4 aortic dissection, 11 cerebral infarction, 2 cerebral hemorrhage, 1 transient ischemic attack and 1 arteriosclerosis obliterans). Kaplan-Meier analysis revealed that the freedom from CCVD rate was significantly lower in patients with H-FABP > 3.6 ng/ml (median value) than in those with H-FABP ≤ 3.6ng/ml (hazard ratio p=0.001). On a Cox multivariate analysis including 6 variables (male gender, eGFR < 60ml/min/1.73m2, diabetes, smoking and BNP and H-FABP > median value) that were significant predictors of CCVD by univariate analyses, H-FABP > 3.6 ng/ml (hazard ratio 2.37, p=0.03) and eGFR < 60ml/min/1.73m2 (hazard ratio 2.21, p=0.03) were independent predictors of future CCVD. Conclusion: H-FABP is a novel and useful marker for the prediction of future CCVD beyond conventional risk factors in patients with essential HT.
No takes yet. Share an insight, caveat, or question.
Setsuta et al. (2013) conducted a cohort in essential hypertension (n=192). H-FABP > 3.6 ng/ml vs. H-FABP ≤ 3.6 ng/ml was evaluated on cerebro-cardiovascular disease (CCVD) (HR 2.37, p=0.03). Elevated H-FABP was an independent predictor of future cerebro-cardiovascular disease in patients with essential hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: